Vivos Therapeutics (VVOS) Change in Receivables (2020 - 2026)
Vivos Therapeutics (VVOS) reported Change in Receivables of $188000.0 for Q1 2026, down 34.72% year-over-year from $288000.0 in Q1 2025, and up 134.0% on a QoQ basis from -$553000.0 in Q4 2025.
Vivos Therapeutics (VVOS) has 7 years of Change in Receivables data on file, last reported at $188000.0 in Q1 2026.
- Quarterly Change in Receivables fell 34.72% year-over-year to $188000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $117000.0 (down 39.06% YoY) and the FY2025 annual result came in at $217000.0, down 4.82% from the prior year.
- Change in Receivables improved to $188000.0 in Q1 2026 per VVOS's latest filing, from -$553000.0 in the prior quarter.
- Across five years, Change in Receivables topped out at $501000.0 in Q3 2025 and bottomed at -$553000.0 in Q4 2025.
- The 5-year median for Change in Receivables is -$24000.0 (2024), against an average of -$21647.1.
- The widest annual swing landed in 2024, when Change in Receivables slumped 2283.33%; it then soared 749.15% in 2025.
- Tracing VVOS's Change in Receivables over 5 years: stood at -$409000.0 in 2022, then surged by 93.64% to -$26000.0 in 2023, then climbed by 7.69% to -$24000.0 in 2024, then tumbled by 2204.17% to -$553000.0 in 2025, then soared by 134.0% to $188000.0 in 2026.
- Per Business Quant, the three latest VVOS Change in Receivables figures stand at $188000.0 (Q1 2026), -$553000.0 (Q4 2025), and $501000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | 42.00 Mn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | -444.00 Mn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | -13.00 Mn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 117.00 Mn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | 117.90 Mn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | - |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | -124.60 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | -141.00 Mn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 123.50 Mn |
| 10 | Vivos Therapeutics | 9.87 Mn | 7.64 Mn | 3.06 Mn | 188,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 188,000.00 |
| Mar 31, 2026 | 188,000.00 |
| Dec 31, 2025 | -553,000.00 |
| Dec 31, 2025 | -553,000.00 |
| Sep 30, 2025 | 501,000.00 |
| Sep 30, 2025 | 501,000.00 |
| Jun 30, 2025 | -19,000.00 |
| Jun 30, 2025 | -19,000.00 |
| Mar 31, 2025 | 288,000.00 |
| Mar 31, 2025 | 288,000.00 |
| Dec 31, 2024 | -24,000.00 |
| Dec 31, 2024 | -24,000.00 |
| Sep 30, 2024 | 59,000.00 |
| Sep 30, 2024 | 59,000.00 |
| Jun 30, 2024 | -131,000.00 |
| Jun 30, 2024 | -131,000.00 |
| Mar 31, 2024 | 324,000.00 |
| Mar 31, 2024 | 324,000.00 |
| Dec 31, 2023 | -26,000.00 |
| Dec 31, 2023 | -26,000.00 |
| Sep 30, 2023 | -99,000.00 |
| Sep 30, 2023 | -99,000.00 |
| Jun 30, 2023 | 6,000.00 |
| Jun 30, 2023 | 6,000.00 |
| Mar 31, 2023 | -136,000.00 |
| Mar 31, 2023 | -136,000.00 |
| Dec 31, 2022 | -409,000.00 |
| Dec 31, 2022 | -409,000.00 |
| Sep 30, 2022 | 74,000.00 |
| Sep 30, 2022 | 74,000.00 |
| Jun 30, 2022 | -210,000.00 |
| Jun 30, 2022 | -210,000.00 |
| Mar 31, 2022 | -201,000.00 |
| Mar 31, 2022 | -201,000.00 |
| Dec 31, 2021 | -2.63 Mn |
| Dec 31, 2021 | -2.63 Mn |
| Sep 30, 2021 | 372,000.00 |
| Sep 30, 2021 | 372,000.00 |
| Jun 30, 2021 | 1.80 Mn |
| Jun 30, 2021 | 1.80 Mn |
| Mar 31, 2021 | 234,000.00 |
| Mar 31, 2021 | 234,000.00 |
| Dec 31, 2020 | 494,630.00 |
| Dec 31, 2020 | 494,630.00 |
| Sep 30, 2020 | 349,666.00 |
| Sep 30, 2020 | 349,666.00 |
| Jun 30, 2020 | -39,677.00 |
| Jun 30, 2020 | -39,677.00 |
| Mar 31, 2020 | -244,619.00 |
| Mar 31, 2020 | -244,619.00 |